Welcome to our dedicated page for IQVIA Holdings news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
Q² Solutions, a subsidiary of IQVIA, has launched the first self-collection safety lab panel for U.S. clinical trial participants. This service, developed with Tasso Inc, allows patients to collect blood samples at home, enhancing convenience and reducing the need for clinical visits. The initial panel monitors liver function through various enzyme and protein tests. Q² Solutions aims to expand this offering with over a dozen additional safety tests, emphasizing patient-centered design and logistics optimization.
IQVIA Holdings Inc. (NYSE:IQV) is set to announce its third-quarter 2022 financial results before the market opens on October 26, 2022. The management team will host a conference call at 9:00 a.m. ET on the same day, with details available on the IQVIA Investor Relations website. A replay of the webcast will be accessible about two hours after the event. IQVIA is a leader in analytics, technology solutions, and clinical research for life sciences, employing approximately 83,000 individuals in over 100 countries.
IQVIA (NYSE:IQV) announced its Decentralized Clinical Trial (DCT) program is the first to receive GDPR compliance validation from TRUSTArc, enhancing its commitment to data protection in Europe. This validation ensures that personal data in decentralized trials is processed in accordance with GDPR, addressing privacy concerns for participants. The achievement reinforces IQVIA's dedication to delivering decentralized studies while improving diversity and sustainability in clinical development, as emphasized by key executives.
IQVIA announced findings highlighting the benefits of decentralized clinical trials (DCT), demonstrating that they can lead to faster, cheaper, and more engaging trials compared to traditional methods.
The company provided tangible data on 14 metrics, revealing significant reductions in timelines and improved patient engagement. Notable metrics include faster timeframes from Final Protocol to First Patient In and decreased Screen Failure Rates. These insights provide valuable information for sponsors looking to optimize clinical trial designs.
IQVIA Holdings Inc. (NYSE:IQV) will have its chairman and CEO, Ari Bousbib, speak at the Baird 2022 Global Healthcare Conference in New York City on September 14, 2022, at 2:35 p.m. ET. Investors can access a live audio webcast via the IQVIA Investor Relations website, with a replay available later. IQVIA is a global leader in analytics and clinical research services, enhancing healthcare through innovative insights and technology with a workforce of approximately 82,000 across over 100 countries.
IQVIA Holdings Inc. (NYSE:IQV) will feature its CFO, Ron Bruehlman, at the Morgan Stanley Annual Global Healthcare Conference on September 13, 2022, at 11:10 a.m. ET in New York City. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is recognized for its analytics and clinical research services, employing approximately 82,000 individuals across over 100 countries.
GSK and IQVIA have launched Vaccine Track, a new platform to enhance data transparency regarding adult vaccinations in the US. This resource aims to address the decline in adult immunization rates, particularly among minority populations, which saw an 18% drop in overall claims for recommended vaccinations from 2019 to 2021. The platform provides quarterly updates and diverse trend analyses, supporting public health efforts to improve vaccination rates post-pandemic. The initiative emphasizes the importance of vaccination data and could significantly impact public health policy.
IQVIA reported second-quarter 2022 revenue of $3,541 million, a 3.0% increase compared to the previous year, and 7.1% at constant currency. GAAP net income rose by 46.3% to $256 million, with diluted EPS increasing 48.9% to $1.34. Adjusted EBITDA reached $800 million, up 10.8% year-over-year. The R&D Solutions backlog grew 7.1% to $25.6 billion. For full-year guidance, revenue is now expected between $14,400 million and $14,550 million, reflecting 3.8% to 4.9% growth on a reported basis.
IQVIA Holdings Inc. (NYSE:IQV) has announced the upcoming release of its second-quarter 2022 financial results, scheduled for July 21, 2022, before the market opens. A conference call and webcast will follow at 9:00 a.m. Eastern Time that same day. The earnings release and detailed financial information will be available on the IQVIA Investor Relations website. A replay of the webcast will be accessible two hours after the event concludes, further enhancing investor engagement.
FAQ
What is the current stock price of IQVIA Holdings (IQV)?
What is the market cap of IQVIA Holdings (IQV)?
What is IQVIA Holdings Inc.?
What services does IQVIA offer?
How many employees does IQVIA have?
What is IQVIA's focus in the research and development segment?
What is the role of IQVIA's technology and analytics segment?
Does IQVIA conduct virtual clinical trials?
What industries does IQVIA serve?
How does IQVIA protect patient privacy?
Where can I find more information about IQVIA?
When was IQVIA formed?
